Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07292376

Implementing VTE Prevention in Ambulatory Cancer Care

assess effectiveness of a , compared with usual care, to assess

The goal of this study is to learn if a modified clinical program can improve adherence to guideline recommendations for prevention of venous thromboembolism in ambulatory patients with cancer. The main question[s] it aims to answer are:

Does the modified program improve number of ambulatory oncology patients starting systemic treatment getting VTE risk-assessment? Does the modified program improve the number of patients receiving appropriate preventative anticoagulation? Researchers will compare to usual care (no clinical program).

Participant clinicians will be asked to

* receive education about VTE prevention recommendations * carry out risk assessment, anticoagulation discussions, and document the results Participant patients will receive care from clinicians participating in the study as part of their cancer care.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Venous Thromboembolism Cardiovascular Diseases Embolism and Thrombosis Neoplasms Thromboembolism Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Vermont Health

Burlington, Vermont, 05405, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinicians: practicing oncologist at study clinic site (UVMMC)
  • Patients: diagnosis of cancer; starting new systemic cancer-directed therapy at a study clinic site under the direction of the enrolled clinician

Exclusion criteria

  • none

Treatment and study plan

Clinical program

Other

Revised Vermont Model clinical program, including standardized education and training for oncology care team, clinical decision support and revised workflow for VTE risk assessment and thromboprophylaxis.

Primary outcomes

  1. Documented VTE risk assessment

    Time frame: 30 days after new patient appointment

    Proportion of new patients who have documented VTE risk assessment

Secondary outcomes

  1. Appropriate thromboprophylaxis

    Time frame: 30 days after new patient appointment

    Proportion of identified high-risk patients with prescription for thromboprophylaxis and low-risk patients without thromboprophylaxis

Sponsors and collaborators

Lead sponsor

University of Vermont

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 18, 2025
Registry last updated
Dec 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.